TABLE 2.

Risk, Risk Differences, and Their 97.5% CI of Primary End Points at 12 months

Endpoints	Clinician (MD) (N = 845), Number (%)	Nurse (NS) (N = 841), Number (%)	Risk Difference (NS-MD), (Point Estimate, 97.5% CI)
Individual Outcomes
Died	8/845 (0.9)	11/841 (1.3)	0.4 (−1.1 to 0.9)
LTFU	213/845 (25.2)	191/841 (22.7)	1.7 (−1.9 to 4.9)
Toxicity	8/845 (0.9)	8/841 (0.9)	−0.1 (−1.1 to 0.9)
VF*	46/548 (8.4)	48/570 (8.4)	0.4 (−3.3 to 4.0)
Composite outcome
Intention-to-treat analysis (complete cases analysis)	259/692 (37.4)	233/699 (33.3)	−4.1 (−9.8 to 0.2)
Intention-to-treat analysis (MI)	314/845 (37.2)	284/841 (33.8)	−3.4 (−9.1 to 2.5)
Per-protocol analysis	257/685 (37.5)	232/685 (33.9)	−3.6 (−10.5 to 0.6)
Per-protocol analysis (MI)	303/815 (37.2)	274/803 (34.1)	−3.1 (−8.8 to 2.8)

Risk difference = Risk in nurse arm − Risk among clinician arm.

Total individual events may not add up to total composite events because a patient could have multiple events, thus were counted once. Seventy-four participants in WHO stage 3/4 enrolled in error, thus excluded from both intention-to-treat and per-protocol analyses.

VF = virological failure.

^*Missing data; VF: (clinician = 297/845, nurse = 271/841), composite (clinician = 153/845, nurse = 142/841).